Dosing and uses of Alomide (lodoxamide ophthalmic)
Adult dosage forms and strengths
ophthalmic solution
- 0.1%
Vernal Keratoconjunctivitis
1-2 drops in affected eye QID for up to 3 months
Vernal Conjunctivitis
1-2 drops in affected eye QID for up to 3 months
Vernal Keratitis
1-2 drops in affected eye QID for up to 3 months
Other Information
Each 1mL contains 1.78 mg lodoxamide tromethamine equivalent to 1 mg lodoxamide
Pediatric dosage forms and strengths
ophthalmic solution
- 0.1%
Vernal Keratoconjunctivitis
<2 years: safety and efficacy not established
>2 years: 1-2 drops in affected eye QID for up to 3 months
Vernal Conjunctivitis
<2 years: safety and efficacy not established
>2 years: 1-2 drops in affected eye QID for up to 3 months
Vernal Keratitis
<2 years; safety and efficacy not established
>2 years: 1-2 drops in affected eye QID for up to 3 months
Alomide (lodoxamide ophthalmic) adverse (side) effects
>10%
Transient local burning (15%)
Transient local stinging (15%)
Transient local discomfort (15%)
1-10%
Headache (1.5%)
Foreign body sensation (1-5%)
Ocular itching/pruritus (1-5%)
Blurred vision (1-5%)
Dry eye (1-5%)
Tearing/discharge (1-5%)
Hyperemia (1-5%)
Crystalline deposits (1-5%)
<1%
Heat sensation
Dizziness
Somnolence
Sneezing
Dry nose
Nausea
Stomach discomfort
Rash
Corneal erosion/ulcer
Scales on lid/lash
Eye pain
Ocular edema/swelling
Ocular warming sensation
Ocular fatigue
Chemosis
Corneal abrasion
Keratopathy/keratitis
Blepharitis
Allergy
Sticky sensation
Epitheliopathy
Warnings
Contraindications
Hypersensitivity to any component
Cautions
For topical ophthalmic use only; not for injection
Contains benzalkonium chloride; remove soft contact lenses during treatment
Pregnancy and lactation
Pregnancy category: B
Lactation: unknown whether distributed in breast milk, caution advised
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Alomide (lodoxamide ophthalmic)
Half-Life
8.5 hrs
Absorption
Systemic absorption minimaL
Excretion
Primarily in urine
Mechanism of action
Lodoxamide tromethamine is a mast cell stabilizer that inhibits the in vivo Type I immediate hypersensitivity reaction; inhibits the increases in cutaneous vascular permeability associated with reagin or IgE and antigen-mediated reactions
